1. |
Bressler NM, Odia I, Maguire M, et al. Association between change in visual acuity and change in central subfield thickness during treatment of diabetic macular edema in participants randomized to aflibercept, bevacizumab, or ranibizumab: a post hoc analysis of the protocol T randomized clinical trial[J]. JAMA Ophthalmol, 2019, 137(9): 977-985. DOI: 10.1001/jamaophthalmol.2019.1963.
|
2. |
Ciulla TA, Pollack JS, Williams DF. Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes[J]. Br J Ophthalmol, 2021, 105(2): 216-221. DOI: 10.1136/bjophthalmol-2020-315933.
|
3. |
Kodjikian L, Bellocq D, Bandello F, et al. First-line treatment algorithm and guidelines in center-involving diabetic macular edema[J]. Eur J Ophthalmol, 2019, 29(6): 573-584. DOI: 10.1177/1120672119857511.
|
4. |
Bressler SB, Glassman AR, Almukhtar T, et al. Five-year outcomes of ranibizumab with prompt or deferred laser versus laser or triamcinolone plus deferred ranibizumab for diabetic macular edema[J]. Am J Ophthalmol, 2016, 164: 57-68. DOI: 10.1016/j.ajo.2015.12.025.
|
5. |
Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the management of diabetic macular edema by the European society of retina specialists (EURETINA)[J]. Ophthalmologica, 2017, 237(4): 185-222. DOI: 10.1159/000458539.
|
6. |
American Academy of Ophthalmology. Diabetic Retinopathy PPP [M]. Amsterdam: Elsevier Inc, 2014.
|
7. |
American Academy of Ophthalmology. Diabetic Retinopathy PPP [M]. Amsterdam: Elsevier Inc, 2017.
|
8. |
American Academy of Ophthalmology. Diabetic Retinopathy PPP [M]. Amsterdam: Elsevier Inc, 2019.
|
9. |
Wong TY, Sun J, Kawasaki R, et al. Guidelines on diabetic eye care: the international council of ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings[J]. Ophthalmology, 2018, 125(10): 1608-1622. DOI: 10.1016/j.ophtha.2018.04.007.
|
10. |
Cheung GC, Yoon YH, Chen LJ, et al. Diabetic macular oedema: evidence-based treatment recommendations for Asian countries[J]. Clin Exp Ophthalmol, 2018, 46(1): 75-86. DOI: 10.1111/ceo.12999.
|
11. |
Chhablani J, Wong K, Tan GS, et al. Diabetic macular edema management in Asian population: expert panel consensus guidelines[J]. Asia Pac J Ophthalmol (Phila), 2020, 9(5): 426-434. DOI: 10.1097/APO.0000000000000312.
|
12. |
Chen JT, Chen LJ, Chen SN, et al. Management of diabetic macular edema: experts' consensus in Taiwan[J]. Jpn J Ophthalmol, 2020, 64(3): 235-242. DOI: 10.1007/s10384-020-00741-4.
|
13. |
Lukic M, Williams G, Shalchi Z, et al. Intravitreal aflibercept for diabetic macular oedema: Moorfields' real-world 12-month visual acuity and anatomical outcomes[J]. Eur J Ophthalmol, 2020, 30(3): 557-562. DOI: 10.1177/1120672119833270.
|
14. |
戴虹, 卢颖毅. 糖尿病黄斑水肿治疗方案的选择及需要关注的几个问题[J]. 中华实验眼科杂志, 2016, 34(12): 1061-1064. DOI: 10.3760/cma.j.issn.2095-0160.2016.12.002.Dai H, Lu YY. Choice of current approaches to the management of diabetic macular edema[J]. Chin J Exp Ophthalmol, 2016, 34(12): 1061-1064. DOI: 10.3760/cma.j.issn.2095-0160.2016.12.002.
|
15. |
卢颖毅, 戴虹. 从最新的指南看糖尿病黄斑水肿的治疗策略和方案[J]. 中华实验眼科杂志, 2018, 36(6): 401-403. DOI: 10.3760/cma.j.issn.2095-0160.2018.06.001.Lu YY, Dai H. Treatment strategy and plan for diabetic macular edema based on the latest guidelines[J]. Chin J Exp Ophthalmol, 2018, 36(6): 401-403. DOI: 10.3760/cma.j.issn.2095-0160.2018.06.001.
|
16. |
García Layana A, Adán A, Ascaso FJ, et al. Use of intravitreal dexamethasone implants in the treatment of diabetic macular edema: expert recommendations using a Delphi approach[J]. Eur J Ophthalmol, 2020, 30(5): 1042-1052. DOI: 10.1177/1120672119861623.
|
17. |
Castro Farías D, Matsui Serrano R, Bianchi Gancharov J, et al. Indocyanine green angiography for identifying telangiectatic capillaries in diabetic macular oedema[J]. Br J Ophthalmol, 2020, 104(4): 509-513. DOI: 10.1136/bjophthalmol-2019-314355.
|
18. |
吕林, 陈士达. 微创玻璃体手术时代: 糖尿病视网膜病变手术的新认识[J]. 中华眼底病杂志, 2021, 38(12): 1-5. DOI: 10.3760/cma.j.cn511434-20211206-00681.Lyu L, Chen SD. The era of minimally invasive vitreous surgery: new insights into diabetic retinopathy surgery[J]. Chin J Ocul Fundus Dis, 2021, 38(12): 1-5. DOI: 10.3760/cma.j.cn511434-20211206-00681.
|
19. |
中华医学会糖尿病学分会视网膜病变学组. 糖尿病相关眼病防治多学科中国专家共识(2021年版)[J]. 中华糖尿病杂志, 2021, 13(11): 1026-1042. DOI: 10.3760/cma.j.cn115791-20211006-00534.Retinopathy Group of Diabetes Branch of Chinese Medical Association. Chinese multidisciplinary expert consensus on the prevention and treatment of diabetic eye disease (2021 edition)[J]. Chin J Diabetes Mellitus, 2021, 13(11): 1026-1042. DOI: 10.3760/cma.j.cn115791-20211006-00534.
|
20. |
Korobelnik JF, Daien V, Faure C, et al. Real-world outcomes following 12 months of intravitreal aflibercept monotherapy in patients with diabetic macular edema in France: results from the APOLLON study[J]. Graefe's Arch Clin Exp Ophthalmol, 2020, 258(3): 521-528. DOI: 10.1007/s00417-019-04592-9.
|
21. |
Glassman AR, Wells JA 3rd, Josic K, et al. Five-year outcomes after initial flibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (protocol T extension study)[J]. Ophthalmology, 2020, 127(9): 1201-1210. DOI: 10.1016/j.ophtha.2020.03.021.
|
22. |
赵晶, 戴虹. 中国抗血管内皮生长因子药物眼科临床应用现状及存在问题[J]. 临床药物治疗杂志, 2020, 18(12): 1-5. DOI: 10.3969/j.issn.1672-3384.2020.12.001.Zhao J, Dai H. Status and challenges of anti-vascular endothelial growth factor usage in ophthalmic diseases in China[J]. Clinical Medication Journal, 2020, 18(12): 1-5. DOI: 10.3969/j.issn.1672-3384.2020.12.001.
|
23. |
Bressler NM, Beaulieu WT, Glassman AR, et al. Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial[J]. JAMA Ophthalmol, 2018, 136(3): 257-269. DOI: 10.1001/jamaophthalmol.2017.6565.
|
24. |
许迅, 黎晓新. 我国眼底病专业领域发展70年回顾[J]. 中华眼科杂志, 2020, 56(4): 241-245. DOI: 10.3760/cma.j.cn112142-20200207-00051.Xu X, Li XX. A summary of ocular fundus diseases in China over the past 70 years[J]. Chin J Ophthalmol, 2020, 56(4): 241-245. DOI: 10.3760/cma.j.cn112142-20200207-00051.
|